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Abstract
In 2007, a significant increase in acquired ampC genes in Entero-
bacteriaceae from 0.06% in 1999 to 1.3% was observed. Proteus
mirabilis showed the highest prevalence (0.95%) and CMY-2 was
the most prevalent AmpC enzyme (66.7%). Other enzymes such
as CMY-4, DHA-1, ACC-1, and three new enzymes called CMY-
25, CMY-27 and CMY-40 were detected. Seven out of the 117
isolates (6%) also produced an extended-spectrum b-lactamase.
As acquired AmpC enzymes are likely to become a serious
public health issue worldwide, close surveillance is necessary to
curb their spread.
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Acquired AmpCs appeared in the late 1980s and have been
detected mainly in isolates of Klebsiella spp., Escherichia coli,
Proteus mirabilis and Salmonella spp. although they have also
been identified in other species including natural AmpC
producers [1]. These enzymes confer resistance to most
b-lactams – including cephamycins – with the exception of
cefepime and carbapenems [2].
Most acquired ampCs derive from chromosomal ampC
genes of the family Enterobacteriaceae (Citrobacter freundii,
Enterobacter spp., Morganella morganii and Hafnia alvei)
whereas the origin of others remains unknown. Isolates har-
bouring acquired ampCs are usually multi-resistant [3–6], lim-
iting the therapeutic options even further. In this context,
we aimed to determine the prevalence of acquired AmpCs
in Enterobacteriaceae isolates lacking inducible chromosomal
ampC genes at a Spanish hospital from January 1999 to
December 2007.
Isolates were obtained from routine cultures at the Hospi-
tal de la Santa Creu i Sant Pau (Barcelona, Spain). When
there were multiple isolates from a patient within a 30-day
period, only one was considered for analysis. Isolates were
identified using standard methods [7]. The disc diffusion sus-
ceptibility test was performed according to Clinical Labora-
tory Standards Institute (CLSI) guidelines [8], using
commercially available discs (Bio-Rad, Marnes La Coquette,
France). The production of Extended-spectrum beta-lacta-
mase (ESBL) was studied using the double-disc synergy test
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and confirmed when necessary by Etest ESBL (AB Biodisk,
Solna, Sweden) [3,9].
As some acquired AmpCs do not confer resistance to
cefoxitin, the strains selected for this study were those
showing intermediate resistance or resistance to amoxicillin-
clavulanic acid, cefotaxime or ceftazidime according to CLSI
breakpoints [8], and negative results for ESBL production.
Isolates which screened positive for ESBL production and
showed intermediate susceptibility or resistance to amoxicil-
lin-clavulanic or cefoxitin were also included [10]. Acquired
AmpCs were characterized using the previously described
multiplex PCR [2]. Amplicons were purified and sequenced as
described previously [9]. PCR-positive isolates were tested
using a double-disc synergy test based on the utilization of
cloxacillin (500 lg) as inhibitor of AmpC enzymes (except
Escherichia coli strains). All PCR-positive isolates were also
tested for the presence of scattered colonies in the inhibition
halo of cefoxitin, cefotaxime, ceftazidime and aztreonam [10].
Among the 27 119 isolates of Enterobacteriaceae lacking
inducible chromosomal AmpC b-lactamases, 437 isolates
were studied as putative acquired AmpC producers. We
obtained amplicons in 117: 75 E. coli, 20 P. mirabilis, 16 K.
pneumoniae, four K. oxytoca and two S. enterica. The remain-
ing 320 isolates were ESBL producers, hyperproducers of
chromosomal AmpC enzymes (E. coli), or hyperproducers of
class A enzymes (Klebsiella spp.). Moreover, other non-enzy-
matic resistance mechanisms such as altered permeability
may also have been present in these isolates. A few of the
117 isolates included in this study have been described previ-
ously [7,9,10].
The 117 isolates were recovered from urine (66.7%), flu-
ids and tissue (14.5%), blood (10.3%), respiratory tract
(3.4%) or other samples (5.1%). Most samples were from
ambulatory patients (64.1%).
The overall prevalence of Enterobacteriaceae carrying
acquired ampCs was 0.43%, rising from 0.06% (1999) to 1.3%
(2007). This significant increase (p <0.001; contingency table-
chi-square test was used for evaluation; SPSS V15 software;
SPSS Inc., Chicago, IL, USA), which occurred mainly in the last
3 years, could have been as a result of the emergence of
Enterobacteriaceae-producing DHA (16 out of 40 in 2007) and
the increase of CMY-2-producing P. mirabilis. The highest prev-
alence was found in P. mirabilis (0.95%), as in a recent survey
in Polish hospitals where acquired AmpCs were observed
TABLE 2. Prevalence and distribution of acquired AmpCs among Enterobacteriaceae lacking inducible chromosomal ampC
genes
1999 2000 2001 2002 2003 2004 2005 2006 2007 1999–2007
E. coli (n) 2283 2068 1820 2109 2440 2285 2385 2315 2224 n = 19929
CMY-2 1 6 1 1 3 8 4 14a 15 53 (70.7%)
CMY-4 1 1 2 (2.7%)
CMY-27 2a 2 (2.7%)
CMY-40 1 1 (1.3%)
DHA-1 4b 3 8c 15 (20%)
ACC-1 1 1 2 (2.7%)
Total (%) 1 (0.04) 6 (0.29) 1 (0.05) 1(0.05) 3(0.12) 9(0.39) 10 (0.42) 19 (0.82) 25 (1.12) 75 (0.38)
K. pneumoniae (n) 214 222 181 181 288 295 273 339 394 n = 2387
CMY-2 1 1d 1 1 4 (25%)
CMY-25 1 1 (6.3)
DHA-1 2 2 6e 10 (62.5)
ACC-1 1 1 (6.3)
Total (%) 1 (0.44) 1 (0.55) 1 (0.34) 4 (1.46) 3 (0.84) 6 (1.52) 16 (0.67)
P. mirabilis (n) 280 140 201 178 267 249 248 262 270 n = 2095
CMY-2 1 1f 4f,g 6 7f 19 (95%)
DHA-1 1 1 (5%)
Total (%) 1 (0.71) 1 (0.80) 4 (1.21) 7 (2.67) 7 (2.60) 20 (0.95)
K. oxytoca (n) 0 0 45 88 65 70 98 76 87 n = 509
DHA-1 2h 2h 4 (100%)
Total (%) 2 (2.63) 2 (2.30) 4 (0.79)
S. enterica (n) 352 148 290 208 182 231 141 125 94 n = 1771
CMY-2 1 1 2 (100%)
Total (%) 1 (0.28) 1 (0.80) 2 (0.11)
Othersi n = 428
Overall prevalence (%) 0.06 0.31 0.08 0.04 0.09 0.38 0.53 1.01 1.3 0.43
aTwo of these isolates showed identical ERIC and PFGE patterns and spread among patients was established.
bTwo of these isolates showed identical ERIC and PFGE patterns but no epidemiological relationship was established between patients.
cTwo isolates also harboured a CTX-M-14.
dThis isolate also harboured a CTX-M-1.
eThree isolates also harboured a CTX-M-15. Two of these isolates showed identical PFGE patterns. Patient spread was established.
fPFGE results showed a cluster of five P. mirabilis (four identical PFGE and one probably related pattern; all carrying CMY-2). One of these strains was isolated in 2004,
another in 2005 and the remaining three in 2007. No epidemiological relationship was established between patients.
gOne of these isolates also harboured a CTX-M-2 (first report in Catalonia).
hPFGE results showed a cluster of two K. oxytoca (one strain isolated in 2006 and the other in 2007). Both were isolated from the same patient over an interval of
8 months.
iThe species included here are: C. koseri (211 isolates), Shigella spp. (101 isolates), P. vulgaris (108 isolates) and P. penneri (eight isolates). No acquired AmpCs were found.
474 Clinical Microbiology and Infection, Volume 16 Number 5, May 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 470–476
exclusively in P. mirabilis (20.5%) [11]. Other studies found no
acquired-AmpC-producing P. mirabilis [5] or found it at
a lower rate (0.75%) [12]. It is of note that in our setting,
P. mirabilis is acquiring different types of b-lactamases, including
AmpCs [9].
CMY-2 has a worldwide distribution. In our study, it was
the predominant enzyme (66.7%), followed by DHA-1
(25.6%). DHA-1 was mainly associated with Klebsiella spp.
and was the only acquired AmpC detected in K. oxytoca. Less
commonly found enzymes were ACC-1, CMY-4, CMY-25,
CMY-27 and CMY-40. The last three are reported here for
first time (their amino acid substitutions and the correspond-
ing susceptibility test results are shown in Table 1). Seven
(6%) out of the 117 acquired-AmpC-producing isolates also
produced an ESBL (Table 2). The prevalence and type of
acquired AmpCs differs depending upon the geographical
area, the species studied and the period of study [4,11–14],
possibly as a result of the selection criteria used. For this
reason, it is difficult to compare the prevalence of acquired
AmpCs between studies.
Resistance of the AmpC-producers to non-b-lactam anti-
biotics was high. Isolates showed resistance to nalidixic acid
(74.4%), ciprofloxacin (51.3%), tetracycline (67.5%), chlor-
amphenicol (43.6%), sulphonamides (61.5%), trimethoprim
(43.6%) and aminoglycosides such as streptomycin (52.1%),
kanamycin (43.6%), gentamicin (36.7%) and tobramycin (34.2%).
The cloxacillin test was positive for all analysed isolates.
Using the disc diffusion method, 86.3% of isolates showed an
inhibition halo to third-generation cephalosporins (13–33 mm)
and aztreonam (13–43 mm). Most of these (91.1%) showed
scattered colonies near the edge of the inhibition zones. Both
these phenotypic tests are useful to detect the presence of
acquired AmpCs in Enterobacteriaceae lacking inducible chro-
mosomal AmpC. Nevertheless, as previously reported [15],
the cloxacillin test does not allow differentiation between
chromosomal and acquired AmpC enzymes. PCR is the still
the most reliable test in these cases.
The clonal diffusion of these enzymes was analysed by
clinical and molecular epidemiology. Enterobacterial repeti-
tive intergenic consensus (ERIC)-PCR was used as a first
approach for E. coli strains [2,9]. Those that showed ERIC
patterns with >80% homology were then analysed by pulsed-
field gel electrophoresis (PFGE) [3]. PFGE was also used to
study the clonal relationship of the remaining isolates.
Results are shown in Table 2.
Acquired-AmpC-producing organisms are likely to remain
undetected in many clinical laboratories as there is a lack of
standardized phenotypic methods [10,16]. In a multi-centre
Spanish study, only 53.2% of 57 laboratories were able to
detect E. coli and K. pneumoniae producing acquired AmpC [17].
There are very few reports from Europe regarding the epi-
demiology of acquired-AmpCs over a period of several years
[4], and to date, this is the first from Spain. Our findings sup-
port the view that the prevalence and diversity of acquired
ampC genes is increasing. Knowledge about the prevalence
and diffusion of this emergent resistance may be helpful to
establish preventive measures that will curb their spread.
Nucleotide Sequence Accession Number
The new b-lactamase gene sequences were submitted to the
GenBank under accession numbers EU515249 (blaCMY-25),
EU515250 (blaCMY-27) and EU515251 (blaCMY-40).
Acknowledgements
We thank C. Newey for revising the English.
Transparency Declaration
This study was partially supported by Ministerio de Sanidad y
Consumo, Instituto de Salud Carlos III—FEDER, Spanish
Network for the Research in Infectious Diseases (REIPI C03/
14) and Spanish Network for the Research in Infectious Dis-
eases (REIPI RD06/0008). The authors declare that they have
no conflict of interest.
References
1. Philippon A, Arlet G, Jacoby A. Plasmid-determined AmpC-Type b-
lactamases. Antimicrob Agents Chemother 2002; 46: 1–11.
2. Pe´rez-Pe´rez FJH, Hanson ND. Detection of plasmid-mediated AmpC
b-lactamase genes in clinical isolates by using multiplex PCR. J Clin
Microbiol 2002; 40: 2153–2162.
3. Blanc V, Mesa R, Saco M et al. ESBL- and plasmidic class C b-lactam-
ase-producing E. coli strains isolated from poultry, pig and rabbit
farms. Vet Microbiol 2006; 118: 299–304.
4. Hopkins KL, Batchelor MJ, Liebana E, Deheer-Graham AP, Threlfal
EJ. Characterisation of CTX-M and AmpC genes in human isolates of
Escherichia coli identified between 1995 and 2003 in England and
Wales. Int J Antimicrob Agents 2006; 28: 180–192.
5. Song W, Kim JS, Kim HS et al. Increasing trend in the prevalence of
plasmid-mediated AmpC b-lactamases in Enterobacteriaceae lacking
chromosomal ampC gene at a Korean university hospital from 2002
to 2004. Diagn Microbiol Infect Dis 2006; 55: 219–224.
6. Pitout JD, Gregson DB, Church DL, Laupland KB. Population-based
laboratory surveillance for AmpC b-lactamase-producing Escherichia
coli, Calgary. Emerg Infect Dis 2007; 13: 443–448.
7. Navarro F, Pe´rez-Trallero E, Marimo´n JM, Aliaga R, Gomariz M, Mir-
elis B. CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Kle-
bsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in
CMI Research Notes 475
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 470–476
Spain (October 1999–December 2000). J Antimicrob Chemother 2001;
48: 383–389.
8. Clinical and Laboratory Standards Institute (CLSI). Performance stan-
dards for antimicrobial susceptibility testing: Seventeenth Informational
(suppl) M100-S17.PA, USA: CLSI, Wayne, 2007.
9. Arago´n LM, Mirelis B, Miro´ E et al. Increase in b-lactam-resistant Pro-
teus mirabilis strains due to CTX-M and CMY-type as well as new
VEB- and inhibitor-resistant TEM-type b-lactamases. J Antimicrob Che-
mother 2008; 61: 1029–1032.
10. Mirelis B, Rivera A, Miro´ E, Mesa RJ, Navarro F, Coll P. A simple
phenotypic method for differentiation between acquired and chromo-
somal AmpC b-lactamases in Escherichia coli. Enferm Infecc Microbiol
Clin 2006; 24: 370–372.
11. Empel J, Baraniak A, Literacka E et al. and the Beta-PL Study Group.
Molecular survey of b-lactamases conferring resistance to newer b-
lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob
Agents Chemother 2008; 52: 2449–2454.
12. Adler H, Fenner L, Walter P et al. Plasmid-mediated AmpC b-lacta-
mases in Enterobacteriaceae lacking inducible chromosomal ampC
genes: prevalence at a Swiss university hospital and occurrence of
the different molecular types in Switzerland. J Antimicrob Chemother
2008; 61: 457–458.
13. A´lvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjuga-
tive plasmid-mediated AmpC b-lactamase in the United States. Anti-
microb Agents Chemother 2004; 42: 533–537.
14. Woodford N, Reddy S, Fagan EJ et al. Wide geographic spread of
diverse acquired AmpC b-lactamases among Escherichia coli and Klebsi-
ella spp. in the UK and Ireland. J Antimicrob Chemother 2007; 59: 102–105.
15. Yen Tan T, Yong LS, He J, Hsien T, Yang L. Evaluation of screening
methods to detect plasmid-mediated AmpC in Escherichia coli, Klebsiel-
la pneumoniae and Proteus mirabilis. Antimicrob Agents Chemother 2009;
53: 146–149.
16. Hanson ND. AmpC b-lactamases: what do we need to know for the
future? J Antimicrob Chemother 2003; 52: 2–4.
17. Conejo MC, Mata C, Navarro F, Pascual Aand the GEMARA collabora-
tive group. Detection and reporting betalactam resistance phenotypes
in Escherichia coli and Klebsiella pneumoniae: a multicentre proficiency
study in Spain. Diagn Microbiol Infect Dis 2008; 62: 317–325.
476 Clinical Microbiology and Infection, Volume 16 Number 5, May 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 470–476
